

Product Datasheet

FGL2/Fibroleukin Antibody (6D9) - Azide and BSA Free H00010875-M01

Unit Size: 0.1 mg

Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Publications: 26

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/H00010875-M01

Updated 9/9/2025 v.20.1

**Earn rewards for product
reviews and publications.**

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/H00010875-M01




H00010875-M01

FGL2/Fibroleukin Antibody (6D9) - Azide and BSA Free


Product Information	
Unit Size	0.1 mg
Concentration	Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Storage	Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
Clonality	Monoclonal
Clone	6D9
Preservative	No Preservative
Isotype	IgG2a Kappa
Purity	Protein A purified
Buffer	In 1x PBS, pH 7.4
Product Description	
Description	Novus Biologicals Mouse FGL2/Fibroleukin Antibody (6D9) - Azide and BSA Free (H00010875-M01) is a monoclonal antibody validated for use in IHC, WB, ELISA, Flow, ICC/IF and IP. Anti-FGL2/Fibroleukin Antibody: Cited in 26 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Mouse
Gene ID	10875
Gene Symbol	FGL2
Species	Human, Mouse, Rat
Specificity/Sensitivity	FGL2 (6D9)
Immunogen	FGL2 (NP_006673, 24 a.a. ~ 123 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. NNETEEIKDERAKDVCPVRLESRGKCEEAGECPYQVSLPPLTIQLPKQFSRIEE VFKEVQNLKEIVNSLKKSCQDCKLQADDNGDPGRNGLLLPSTGAPG
Notes	This product is produced by and distributed for Abnova, a company based in Taiwan.
Product Application Details	
Applications	Western Blot, Immunohistochemistry-Paraffin, ELISA, Flow Cytometry, Functional, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunoprecipitation
Recommended Dilutions	Western Blot 1:500, Flow Cytometry, ELISA 1:100-1:2000, Immunohistochemistry 1:10-1:500, Immunocytochemistry/ Immunofluorescence, Immunoprecipitation 1:10-1:500, Immunohistochemistry-Paraffin 0.5ug/mL, Functional
Application Notes	Antibody reactive against cell lysate, transfected lysate and recombinant protein for Western Blot.

Images


Western Blot: FGL2/Fibroleukin Antibody (6D9) [H00010875-M01] - FGL2 monoclonal antibody (M01), clone 6D9. Analysis of FGL2 expression in Raw 264.7.




Immunohistochemistry-Paraffin: FGL2/Fibroleukin Antibody (6D9) [H00010875-M01] - Analysis of monoclonal antibody to FGL2 on formalin-fixed paraffin-embedded human stomach. Antibody concentration 0.5 ug/ml.




Western Blot: FGL2/Fibroleukin Antibody (6D9) [H00010875-M01] - FGL2 monoclonal antibody (M01), clone 6D9 Analysis of FGL2 expression in HeLa.




Western Blot: FGL2/Fibroleukin Antibody (6D9) [H00010875-M01] - FGL2 monoclonal antibody (M01), clone 6D9. Analysis of FGL2 expression in PC-12.




Western Blot: FGL2/Fibroleukin Antibody (6D9) [H00010875-M01] - Analysis of FGL2 expression in transfected 293T cell line by FGL2 monoclonal antibody (M01), clone 6D9. Lane 1: FGL2 transfected lysate (50 KDa). Lane 2: Non-transfected lysate.




Immunoprecipitation: FGL2/Fibroleukin Antibody (6D9) [H00010875-M01] - Analysis of FGL2 transfected lysate using anti-FGL2 monoclonal antibody and Protein A Magnetic Bead, and immunoblotted with FGL2 MaxPab rabbit polyclonal antibody.




ELISA: FGL2/Fibroleukin Antibody (6D9) [H00010875-M01] - Detection limit for recombinant GST tagged FGL2 is approximately 0.1ng/ml as a capture antibody.



Inhibition of Fgl2 signaling improves the antitumor effect of immune checkpoint inhibitors. (A–H) MC38 tumor cells were injected subcutaneously into C57BL/6 mice, the mice were administered 100 μ g anti-FGL2 (α FGL2) or IgG every 3 days after the tumor size reached 100 mm³. Tumor growth (A), survival of MC38 tumor-bearing mice (B, n=9–10), percentage of CD4⁺ and CD8⁺ T cells (C), MDSCs (D), absolute number of G-MDSC and M-MDSC cells (E), macrophages (F) and DCs (G) in tumors, Filipin III staining of MDSCs (H), n=5. (I–M) WT mice were subcutaneously injected with MC38 tumor cells. Tumor-bearing mice were injected with IgG, anti-Fgl2 (α Fgl2), anti-PD-L1 (α PD-L1), or a combination of α FGL2 and anti-PD-L1 (α F+P). Tumor growth was monitored (I), and the percentages of CD8⁺ T cells (J), MDSCs (K), CD8⁺ T cells producing IFN- γ (L) and GzmB (M) in the tumor tissues were analyzed by FCM (n=5). (N) Fgl2 promotes the generation and immune suppressive effects of MDSCs via cholesterol metabolism and XBP1 signaling. Data are expressed as mean \pm SD. *p<0.05; **p<0.01; ***p<0.001; ns, no significant difference, by two-tailed unpaired Student's t-test (A, C–H), log-rank (Mantel-Cox) test (B), one-way or two-way analysis of variance with Sidak multiple comparisons test was used to evaluate statistical significance (I–M). FCM, flow cytometry; Fgl2, fibrinogen-like protein 2; G-MDSCs, granulocytic myeloid-derived suppressor cell; KO, knockout; MDSCs, myeloid-derived suppressor cells; M-MDSC, monocytic myeloid-derived suppressor cell; WT, wild-type. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/38056898>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Inhibition of Fgl2 signaling improves the antitumor effect of immune checkpoint inhibitors. (A–H) MC38 tumor cells were injected subcutaneously into C57BL/6 mice, the mice were administered 100 μ g anti-FGL2 (α FGL2) or IgG every 3 days after the tumor size reached 100 mm³. Tumor growth (A), survival of MC38 tumor-bearing mice (B, n=9–10), percentage of CD4⁺ and CD8⁺ T cells (C), MDSCs (D), absolute number of G-MDSC and M-MDSC cells (E), macrophages (F) and DCs (G) in tumors, Filipin III staining of MDSCs (H), n=5. (I–M) WT mice were subcutaneously injected with MC38 tumor cells. Tumor-bearing mice were injected with IgG, anti-Fgl2 (α Fgl2), anti-PD-L1 (α PD-L1), or a combination of α FGL2 and anti-PD-L1 (α F+P). Tumor growth was monitored (I), and the percentages of CD8⁺ T cells (J), MDSCs (K), CD8⁺ T cells producing IFN- γ (L) and GzmB (M) in the tumor tissues were analyzed by FCM (n=5). (N) Fgl2 promotes the generation and immune suppressive effects of MDSCs via cholesterol metabolism and XBP1 signaling. Data are expressed as mean \pm SD. *p<0.05; **p<0.01; ***p<0.001; ns, no significant difference, by two-tailed unpaired Student's t-test (A, C–H), log-rank (Mantel-Cox) test (B), one-way or two-way analysis of variance with Sidak multiple comparisons test was used to evaluate statistical significance (I–M). FCM, flow cytometry; Fgl2, fibrinogen-like protein 2; G-MDSCs, granulocytic myeloid-derived suppressor cell; KO, knockout; MDSCs, myeloid-derived suppressor cells; M-MDSC, monocytic myeloid-derived suppressor cell; WT, wild-type. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/38056898>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

- Wu L, Liu X, Lei J et al. Fibrinogen-like protein 2 promotes tumor immune suppression by regulating cholesterol metabolism in myeloid-derived suppressor cells *J Immunother Cancer* 2023-01-01 [PMID: 38056898]
- Xiaoying Y, Yaying S, Ze W et al. Proteinase-activated receptor-1 antagonist attenuates brain injury via regulation of FGL2 and TLR4 after intracerebral hemorrhage in mice. *Neuroscience*. 2022-02-17 [PMID: 35182700]
- Shun W, Meng L, Feng X et al. Fibrinogen-like protein 2 deficiency aggravates renal fibrosis by facilitating macrophage polarization. *Biomed Pharmacother*. 2020-08-11 [PMID: 32795921]
- Yekaterina O, Yuliya P, Aikyn K et al. Fc Receptor is Involved in Nk Cell Functional Anergy Induced by Miapaca2 Tumor Cell Line. *Immunol Invest*. 2020-08-30 [PMID: 32865068]
- Xitang L, Qiang G, Wenhui W et al. FGL2-MCOLN3-Autophagy Axis-Triggered Neutrophil Extracellular Traps Exacerbate Liver Injury in Fulminant Viral Hepatitis. *Cell Mol Gastroenterol Hepatol*. 2022-01-01 [PMID: 35926777]
- Shalev I, Wong K, Foerster K et al. The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis. *Hepatology*. 2009-02-15 [PMID: 19085958]
- Ran T, Meiwen H, Wei Y et al. Fibrinogen-like protein 2 promotes proinflammatory macrophage polarization and mitochondrial dysfunction in liver fibrosis. *Int Immunopharmacol*. 2023-03-04 [PMID: 36878044]
- Lianjing H, Di Z, Ying X et al. FGL2 deficiency alleviates maternal inflammation-induced blood-brain barrier damage by blocking PI3K/NF- κ B mediated endothelial oxidative stress. *Front Immunol*. 2023-03-27 [PMID: 37051251]
- Cildir G, Toubia J, Yip K et al. Genome-wide Analyses of Chromatin State in Human Mast Cells Reveal Molecular Drivers and Mediators of Allergic and Inflammatory Diseases. *Immunity*. 2019-10-22 [PMID: 31653482]
- Zhu Y, Zhou J, Feng Y et al. Control of Intestinal Inflammation, Colitis-Associated Tumorigenesis, and Macrophage Polarization by Fibrinogen-Like Protein 2. *Front Immunol*. 2018-01-30 [PMID: 29441068]
- Cherny, I;Hasin, P;Philosoph, LK;Shahal-Zimra, Y;Gurion, R;Rabizadeh, E; Presence and activity of Fibrinogen like protein 2 in platelets *PloS one* 2023-05-18 [PMID: 37200306]
- Shiming J, Nie T, Chengyu Z et al. The Distinctive Role of Membrane Fibrinogen-like Protein 2 in the Liver Stage of Rodent Malaria Infections. *Parasite Immunol*. 2022-10-27 [PMID: 36300695]
- More publications at <http://www.novusbio.com/H00010875-M01>





Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to H00010875-M01

NB800-PC1	HeLa Whole Cell Lysate
NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
HAF007	Goat anti-Mouse IgG Secondary Antibody [HRP]
NB7539	Goat anti-Mouse IgG (H+L) Secondary Antibody [HRP]
NBP1-96981-0.5mg	Mouse IgG2a Kappa Isotype Control (M2AK)

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/H00010875-M01

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

